Irene De Santo

Benevento, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region.

Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.

PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.

Journal: Frontiers in genetics

Published: August 13, 2024

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.

Journal: ESMO open

Published: December 28, 2023

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.

Journal: ESMO open

Published: February 16, 2023

Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.

Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.

Journal: Cancers

Published: February 17, 2022

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].

Journal: ESMO open

Published: April 30, 2021

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).

Journal: ESMO open

Published: November 15, 2020

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.

Journal: Journal for immunotherapy of cancer

Published: August 08, 2020

A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.

A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.

Journal: Clinical breast cancer

Published: June 07, 2020

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy.

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy.

Journal: Cancers

Published: October 22, 2019

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 08, 2019

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.

Journal: Frontiers in oncology

Published: May 10, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026